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Abstract
Studies on traditional serrated adenoma (TSA) and sessile serrated adenoma with dysplasia (SSA-D) are rare due
to the low frequency of these lesions, which are well defined by the latest WHO classification. However, introduc-
ing new morphological criteria such as intra-epithelial lymphocytes (IELs) might facilitate colorectal polyp diag-
noses. Additionally, the phenotype–genotype correlation needs to be updated as the terminology has repeatedly
changed. This study analysed 516 polyps, consisting of 118 classical adenomas (CAD), 116 hyperplastic polyps
(HPP), 179 SSAs, 41 SSA-Ds, and 62 TSAs. The lesions were analysed in relation to the patients’ clinical parame-
ters including gender, age, localisation, and size. The inflammatory background of the polyps was quantified and
BRAF and KRAS mutations as well as MLH1 and CDKN2A promoter methylation were assessed. In multivariate
analyses, an increase in IELs was an independent and robust new criterion for the diagnosis of SSA-D (p< 0.001).
Superficial erosions and acute neutrophil granulocytes led to reactive changes potentially resembling dysplasia.
KRAS and BRAF mutations were associated with CAD/TSA and HPP/SSA, respectively. However, almost half of
TSAs had a BRAF mutation and were KRAS wild type. CDKN2A seems to precede MLH1 hyper-methylation within
the serrated carcinogenesis model. The genotyping of WHO-based entities – and especially SSA – has sharpened
in comparison to previously published data. TSAs can be sub-grouped according to their mutation status. Of note,
the higher number of IELs in SSA-D reflects their close relationship to colorectal cancers with micro-satellite
instability. Therefore, IELs might represent a new diagnostic tool for SSA-D.
Keywords: intra-epithelial lymphocytes; sessile serrated adenoma with dysplasia; sessile serrated adenoma; traditional serrated ade-
noma; BRAF; KRAS; micro-satellite instability
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Introduction
According to the 2010 WHO classification of
Tumours of the Digestive System, serrated colorectal
lesions can be separated from classical adenoma
(CAD) and sub-divided into hyperplastic polyps
(HPP), sessile serrated adenoma (SSA) without and
with dysplasia (SSA-D), and traditional serrated ade-
noma (TSA) [1].
There is evidence that some of these serrated
lesions lead to certain subtypes of colorectal cancer
(CRC), which account for interval carcinomas found
during endoscopic surveillance programmes and
which are biologically different from the classical
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Vogelstein model for CRC [2]. Recently, comprehen-
sive molecular analysis of CRC revealed this CRC
subtype to be a hyper-mutator type with a high fre-
quency of micro-satellite instability (MSI) [3,4].
However, for many practicing pathologists, defini-
tion of the different subsets of serrated precursor
lesions in the colon has created considerable confu-
sion over the years. The background of this process
in terminology has been summarized by others
[1,5–7]. In brief, the initial definition as ‘serrated
adenoma’ from Longacre and Fenoglio-Preiser [8]
has been replaced by Torlakovic et al, who defined
TSA and SSA as two different types of serrated ade-
noma [9]. As a consequence, the term ‘serrated ade-
noma’ should no longer be used without this
distinction.
Subsequently, the lack of cytological dysplasia in
SSA caused issues for routine gastrointestinal
experts, who had thus far used the term adenoma in
the colon only for those lesions that showed classical
features such as hyper-chromasia, elongated pencil-
late nuclei and pseudo-stratification. Thus, misleading
terms were used such as ‘large hyperplastic polyps’
[10,11], which under-estimates the lesions as true
precursors; ‘mixed polyps’ [1,6], which evokes the
impression of collision tumours rather than progres-
sive lesions; or ‘intermediate serrated polyp’ [12], an
example of individual terminology introduced by sin-
gle groups. In the end, the terms SSA and TSA were
retained, but controversy continues regarding the syn-
onymy of SSA with sessile serrated polyps or sessile
serrated lesions (SSL) [1,5].
In terms of semantic precision, the latter might be
the most accurate definition, as the lesion is neither a
true polyp due to its sessile nature nor for many a
true dysplastic adenoma. In particular, the British
guidelines favour the term SSL instead of SSA [13].
However, epidemiological studies have shown that
beyond true cytological dysplastic lesions (SSA-D),
large-sized SSAs (>1.0 cm) even without cytological
dysplasia behave like true precursor lesions [14].
Therefore, arguments regarding the use of the inte-
grated term ‘adenoma’ for these lesions on the basis
of architectural dysplasia as in other organs were fol-
lowed in the WHO classification [1,5].
During the last 25 years of attempts to determine
the most appropriate sub-groups of serrated colorectal
lesions, both molecular features and distinct morpho-
logical features have been investigated. Simply
stated, if changes are made to the classification of
underlying lesions, the effects on molecular distinc-
tions have to be re-evaluated and the phenotype–
genotype correlation updated.
Hence, little is known about how the introduction
of the latest WHO classification might have influ-
enced the molecular distinction between colorectal
serrated lesions. Therefore, we collected a series of
polyps with more of the so far under-represented
SSA-D and TSA lesions and asked for the first time
whether the basic inflammatory response within these
lesions might add new insight into the biological evo-
lution of the serrated carcinogenesis model of CRC,
with a medullary phenotype as a possible endpoint
[2,10,15].
Materials and methods
Meta-analysis
A Pubmed search was performed using the terms
‘Serrated adenoma’, ‘SSA’, ‘TSA’ and ‘SSA-D’ in
combination with either ‘BRAF’ or ‘KRAS’ as fur-
ther classifiers. Next, studies were selected for con-
crete numbers of polyps investigated and attribution
of numbers of BRAF or KRAS mutations. The under-
lying terminology was checked and if not further
explicitly stated the year of the new WHO classifica-
tion 2010 was set as a threshold.
Study collection
The study collection included 516 patients and was
assembled by a search for serrated colorectal lesions
with cytological dysplasia at four different study sites
(Institutes of Pathology of the University Hospital
Erlangen, University Hospital Dresden, Hospital
Bayreuth and Hospital Aschaffenburg, Germany).
H&E slides and corresponding formalin-fixed, paraf-
fin-embedded (FFPE) material for molecular analysis
were further processed at the Institute of Pathology,
University Hospital Erlangen, Erlangen. The compo-
sition of the study collection is outlined in Table 1.
The Declaration of Helsinki and ethical guidelines
were followed (approval numbers Re.-No.3996 and
Re.-No. 4607).
Definition of morphological subtypes
The diagnostic criteria used followed strictly the
2010 WHO classification [1]. The pre-selection of
cases excluded ambiguous lesions that might espe-
cially be found in the spectrum of TSA. So, overlaps
of conventional villous adenomas with partial serra-
tion as well as goblet cell rich TSA were not part of
the study. In TSA, all classical criteria such as hyper-
eosinophilia, ectopic crypt foci, narrow pencillate
nuclei and high overall serration (>50%) were
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fulfilled. In SSA-D, the remnant SSA was defined as
strictly as in non-dysplastic SSA.
Inflammation count
Due to the consumption of tissue for DNA extraction
and molecular analysis, inflammatory cell counts
relied on H&E staining alone. Therefore, only a basic
distinction between granulocytes and lymphocytes
was possible without subtyping. The presence of ero-
sions was stated separately as a possible influencing
factor for the cell numbers detected. Inflammatory
cells were counted in a single hot spot high power
field on a Zeiss Axioskop 2 microscope (Zeiss, Jena,
Germany) with a see field number (SFN) of 23, aper-
ture of 0.575 mm and area of 0.260 mm2 at a 400-
fold magnification.
Molecular analysis
DNA was extracted from two separate 10-lm sec-
tions after macro-dissection using the QIAamp DNA
FFPE Kit (Qiagen, Hilden, Germany). DNA quantity
was assessed with an ND-1000 spectrophotometer
(Thermo Scientific, Wilmington, DE, USA). DNA
quality was analysed by b-globin PCR; primers and
protocols can be provided on request. KRAS and
BRAF mutations were assessed simultaneously using
a multiplex PCR assay, as described previously [6].
MLH1 and p16 methylation analyses were performed
after bisulphite treatment of DNA using the Epitect
Bisulphite Kit (Qiagen, Hilden, Germany). Pyrose-
quencing was undertaken using the MLH1 and
CDKN2A Pyrosequencing Kit each covering five
CpG sites (Qiagen, Hilden, Germany) on a Q24 Pyro-
mark System (Qiagen, Hilden, Germany). Successful
KRAS and BRAF analyses were achieved for all
lesions. Due to advanced DNA degradation only rep-
resentative subsets of the polyp categories were avail-
able for methylation analysis after bisulphite
treatment.
Statistics
The descriptive statistics included Spearman rho cor-
relations, v2 tests, sensitivity, specificity calculations
and, after Kolmogorov–Smirnov–Lillie test for nor-
mal distribution, Student’s t-tests with appropriate
adjustments for paired or unpaired settings. The asso-
ciation of discriminative markers for SSA-D diagno-
sis was analysed with receiver operating
characteristic (ROC) curve and multivariable Cox
regression analysis. The performance of ROC curve
analysis was judged to be better when the area under
the curve (AUC) was closer to 1. Statistical signifi-
cance was assumed at p-values< 0.05. All analyses
were carried out using SPSS 21 (IBM, NY, USA).
Results
Literature study
Using a literature search, 32 studies that conducted
BRAF and/or KRAS analysis on serrated colorectal
polyps between 2003 and 2015 were identified, of
which 31 outlined entity-specific numbers
[6,12,16–44]. The underlying terminology, the date
of appearance and the citations were used to segre-
gate them into pre- and post-WHO classification eras
(Figure 1). Of note, some studies on TSA and SSA-D
were previously sometimes placed in the categories
of serrated adenoma without classifier (SA) or mixed
polyp (MP) (Supplemental Table 1). Since the intro-
duction of the latest WHO classification, a lack of
revised data regarding SSA-D and TSA is evident.
Reflecting the known frequency of approximately
0.8% for truly dysplastic serrated lesions, the under-
lying number of screened colorectal polyps in our
series exceeded n5 5000 [6].
Association with clinical parameters
SSA-D occurred at a significantly later age than SSA
(p< 0.001), with a delay of 12.0 years. This is in
line with data from Fujita et al and Bettington show-
ing a later onset of 8.2 or 17.0 years, respectively
[23,42]. TSA is a later event than CAD (difference
4.7 years, p5 0.004). HPP seems to be the earliest
detectable lesion in the colon, whereas singular SSA
was found as early as age 18. No significant differ-
ence was observed for any lesion in terms of gender.
Table 1. Study collection
Age Size in cm
Polyp n Mean (Range)
Gender
m:f
Site
r:l Mean (Range)
CAD 118 66.9 (42–89) 66:52 66:52 0.7 (0.2–4.0)
-TA 61 66.1 (42–84) 35:26 37:24 0.5 (0.2–1.5)
-TV 54 66.4 (47–89) 28:21 28:26 0.9 (0.4–4.0)
-VA 3 72.3 (70–74) 1:2 1:2 1.0 (0.3–1.4)
HPP 116 62.2 (22–87) 54:62 45:71 0.5 (0.1–2.0)
-GC 31 57.7 (22–87) 13:18 12:19 0.5 (0.1–1.5)
-MD 11 59.3 (44–86) 3:8 7:4 0.5 (0.3–0.8)
-MV 74 62.7 (32–87) 38:36 26:48 0.5 (0.2–2.0)
SSA 179 62.7 (18–93) 82:97 127:52 0.7 (0.2–2.5)
SSA-D 41 73.6 (46–93) 15:26 33:8 1.3 (0.5–4.0)
-CT 28 74.0 (46–93) 12:16 22:6 1.2 (0.5–3.3)
-ST 13 72.9 (47–87) 3:10 11:2 1.4 (0.5–4.0)
TSA 62 71.5 (41–93) 33:29 12:50 1.2 (0.3–6.0)
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As expected, SSA and SSA-D were mostly located in
the right side of the colon (p< 0.001), whereas TSA
and HPP were mostly found on the left (p< 0.001).
CAD did not show any preference for location. Each
step from HPP to SSA to SSA-D revealed a highly
significant increase in diameter (each p< 0.001,
Table 1). Of note, TSA showed the broadest range in
size with rare small lesions and polyps from 0.3 cm
up to 6.0 cm (Table 1). Hyperplastic mucosa could
be found at the edges of 10 out of 61 TSAs even in
large adenomas of 6.0 cm. The average serration in
TSA was 83.5% (range 60–100%).
Inflammatory response mechanisms
As the serrated pathway in CRC is strongly linked to
MSI-high cancers with medullary features and higher
rates of IELs, we tested this H&E criterion in ser-
rated precursor lesions. Additionally, we investigated
the presence of superficial erosions and intra-
epithelial granulocytes (IEGs) (Figure 2 and Supple-
mental Figure 1). Of note, a significant steady
increase in intra-epithelial lymphocytes (IELs) from
HPP to SSA to SSA-D was observed (p5 0.001 and
p< 0.001, respectively). A number of >10 IEL/HPF
seemed to be a reasonable threshold as a distinctive
criterion between SSA and SSA-D based on ROC
analysis (Figure 2A). Whilst IEGs are strongly induc-
ible by surface erosions, IELs are not influenced by
this parameter (Figure 2B). Notably, CAD did not
show increased numbers of IELs. The diagnostic sen-
sitivity of IELs in SSA-D exceeded the performance
of MLH1 or p16 hyper-methylation (Table 2). Histo-
logical details are outlined in Figure 3.
Molecular features of serrated lesions
Data related to the genotype of the colorectal polyps
are outlined in Table 2. As expected, BRAF mutation
was strongly linked to HPP and SSA. There was also
a similar tendency for SSA-D and TSA. Hence, a
BRAF mutation is a strong negative marker for CAD.
In contrast, KRAS mutation was strongly linked to
CAD and TSA and thus is a negative marker for
SSA.
Amongst the 16 KRAS mutations found in HPP,
the distribution in HPP subtypes was 19.4% (6/31) in
goblet cell-rich HPP, 11.1% (1/9) in mucin-depleted
HPP and 12.2% (9/74) in micro-vesicular HPP. The
types of KRAS mutation are shown in Table 3, with a
notable, but still low number of the rare Exon61
mutations in HPP, SSA and SSA-D (Table 3).
Figure 1. Percentage frequencies of BRAF and KRAS mutations across studies before and after the 2010 WHO classification. This
graph highlights the influence of the re-definition of colorectal polyps established by the WHO classification in 2010. No substantial
differences are visible for CAD, TSA and HPP. However, SSA-D shows a very unique and clear pattern based on KRAS and BRAF status
that separates it clearly from the vague previous entities such as MP or SA. More details about the underlying studies are outlined in
Supplemental Table 1.
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In all polyps, BRAF and KRAS mutations were
mutually exclusive. High grade dysplasia in TSA
occurred with BRAF (3/7) or KRAS (4/7) mutations.
Referring to the methylation patterns of MLH1 and
p16 (Table 2), we were first interested in the mean
percentages detected. The 12.9% increase from SSA
to SSA-D was highly significant (p< 0.001). This
difference was also maintained between SSA-D and
TSA (p< 0.001). The means of p16 methylation
showed similar levels for SSA-D and TSA, which
differed significantly from CAD (p< 0.001 each) as
well as HPP (p5 0.001 for SSA-D and p5 0.01 for
TSA).
To translate the mean percentages into a hyper-
methylated versus normal state, we applied the previ-
ously used cut-off of 17% average methylation level,
which was shown to cause transcriptional silencing
[6]. In this context, MLH1 hyper-methylation was
strongly linked to SSA-D, but showed only moderate
sensitivity. p16 hyper-methylation was characteristics
of TSA and SSA-D with good sensitivities. Of note,
MLH1 and CDKN2A hyper-methylation were good
negative markers for CAD.
Correlation of inflammatory response with
methylation patterns
CDKN2A hyper-methylation and MLH1 hyper-
methylation correlated positively across the entire
study (Pearson coefficient 0.382, p< 0.001). Interest-
ingly, there was a strong positive correlation between
MLH1 methylation or CDKN2A hyper-methylation
and IELs (Pearson coefficients 0.265 and 0.113, both
p< 0.001, respectively). Using ROC curve analysis
the IEL counts exceeded the performance of MLH1
hyper-methylation in the distinction of SSA-D from
SSA (Figure 4).
Dissected lesions
Twelve out of the 43 SSA-Ds were suitable for
micro-dissection. No different mutation types were
found when the SSA regions were compared to their
corresponding dysplastic areas. Only one dysplastic
area lacked confirmation of the BRAF mutation
found in its non-dysplastic counter-part. This can be
attributed to the very small dysplastic area in this
particular SSA-D (approximately 5% of the lesion).
The paired comparison of MLH1 and CDKN2A meth-
ylation status as well as the number of IELs and
IEGs are outlined in Figure 5 and revealed a tend-
ency for an increase in MLH1 methylation and a sig-
nificant and remarkable increase in IELs (p5 0.06
and p5 0.01, respectively). Of note, the dissected
non-dysplastic SSA areas showed no significant dif-
ferences in these four parameters in comparison to
the rest of the non-dysplastic SSA areas (p5 0.61,
0.15, 0.60, 0.34, respectively, see also Figure 5).
Multivariate analysis
To test the independence of clinical parameters,
genetics and inflammatory response on the diagnosis
of SSA-D a multivariate analysis was performed inte-
grating all these parameters. According to this analy-
sis, size, age, MLH1 methylation and IEL counts
were independent parameters for the diagnosis of
SSA-D. As expected, granulocytes did not contribute
to any significant diagnostic distinction.
Figure 2. Micro-environment of the inflammatory background
in CAD; HPP; SSA, SSA-D and TSA. (A) Hot spot single counts of
IELs and IEGs per high power field. Note the steady increase in
IELs from HPP to SSA to SSA-D, whereas IEG levels remain
basal. The differences between SSA and SSA-D and between
SSA-D and TSA are highly significant. (B) To exclude an influ-
ence of superficial erosions on the results, we tested the
dependency of IEG and IEL counts on erosions across all polyps.
Whereas IEGs rose significantly if erosions were present, IELs
remained stable. In (C), the IEL status is linked directly to
molecular profiles irrespective of the underlying diagnosis. Of
note, MLH1 hyper-methylation is significantly related to the IEL
response. Unpaired Student’s t-tests, values are outlined as
means with error bars of one standard deviation. BRAF, BRAF
mutation; KRAS, KRAS mutation; MLH1, MLH1 methylation;
p16, CDKN2A methylation
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Figure 3. Histological details in serrated colon polyps with a focus on IELs. Detailed H&E morphology (400x magnification)
showing the low number of IELs in CAD (A) and HPP (B). In direct comparison, areas within SSA-D (C) showed a highly ele-
vated number of IELs, whereas the number in TSAs (D) was only slightly higher than CAD and HPP and still notably lower
than SSA-D.
Table 2. Sensitivity and specificity of molecular parameter
Parameter CAD HPP SSA SSA-D TSA
BRAF mutation
n (2/118) (85/116) (145/179) (31/41) (28/62)
Chi-square test p< 0.001 p< 0.001 p< 0.001 p5 0.010 p5 0.057
Sensitivity 0.017 0.733 0.810 0.756 0.452
Specificity 0.274 0.485 0.567 0.453 0.421
KRAS mutation
n (28/118) (16/116) (6/179) (1/41) (23/62)
Chi-square test p5 0.002 0.747 p< 0.001 p5 0.021 p< 0.001
Sensitivity 0.237 0.138 0.003 0.024 0.387
Specificity 0.879 0.850 0.792 0.842 0.885
MLH1 hypermethylation
Mean6 SD (%) 3.06 2.4 3.06 2.7 4.56 4.4 20.16 21.3 5.76 11.2
n with cut-off> 17% (0/95) (0/66) (2/106) (13/33) (3/52)
Chi-square test p5 0.008 p5 0.036 p5 0.071 p< 0.001 p5 0.816
Sensitivity 0.000 0.000 0.019 0.394 0.057
Specificity 0.930 0.937 0.935 0.984 0.950
CDKN2A hypermethylation
Mean6 SD (%) 8.46 9.0 11.26 14.5 13.76 14.7 22.46 13.3 17.86 13.9
n with cut-off> 17% (16/95) (13/65) (34/108) (22/33) (27/50)
Chi-square test p< 0.001 p5 0.017 p5 0.770 p< 0.001 p< 0.001
Sensitivity 0.189 0.200 0.315 0.667 0.540
Specificity 0.624 0.646 0.669 0.709 0.710
Intraepithelial lymphocytes
n with cut-off> 10/HPF (20/118) (12/116) (55/179) (34/41) (27/62)
Chi-square test p5 0.002 p< 0.001 p< 0.001 p< 0.001 p5 0.004
Sensitivity 0.169 0.103 0.307 0.829 0.435
Specificity 0.686 0.668 0.776 0.766 0.740
118 TT Rau et al
VC 2016 The Authors The Journal of Pathology: Clinical Research published by
The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd
J Path: Clin Res April 2016; 2: 113–124
Discussion
Generally tightened definition and impact of WHO
classification on the phenotype and genotype of
colorectal polyps
Regarding locations, the known predilection for
SSAs and SSA-Ds to occur in the proximal colon
and TSAs in the distal colon was confirmed in this
series with only some exceptions [6]. HPP and CAD
were distributed throughout the colon. The onset and
size differences between SSA and SSA-D are consist-
ent with a recent endoscopy study [45] and indicate a
form of progression in which ageing might play a
crucial role [1,35]. Taking BRAF and KRAS muta-
tions as key mutator events in CRC carcinogenesis,
our study confirms a dichotomized situation. HPP,
SSA and SSA-D are more or less BRAF-associated,
whereas CAD is more prone to involve a KRAS
mutation. TSA shows both events, indicating the pos-
sibility of two different subtypes of TSA [27,46].
Overall our findings confirm previous reports on the
subject [1,6,7].
Unfortunately, a meta-analysis regarding methyla-
tion patterns in colorectal polyps is more difficult to
perform than one at the mutational level as different
methylation assays have been used over time. Addi-
tionally, reports often reported higher CpG island
methylator phenotype (CIMP) status in serrated
lesions as a summarized form of reporting methyla-
tion results [21,35,47,48]. As broadly known, and
depending on its definition, CIMP bundles at least
five different methylation sites of different mechanis-
tic relevance [49,50]. Only few studies highlight
more biologically important gene-related methylation
patterns, allowing a more stepwise understanding of
epigenetic events [19,24]. We chose to use CDKN2A
hyper-methylation as a surrogate marker for cellular
senescence [51], and MLH1 hyper-methylation as the
most common reason for the development of sporadic
micro-satellite instability [24].
Consensus meetings that resulted in the introduc-
tion of the WHO classification concluded that SSA is
a very distinct lesion. It shares molecular similarities
with its advanced counterpart SSA-D, which there-
fore can now be taken out of the pooled entities for-
merly considered as mixed polyps or serrated
adenoma. The mutual exclusivity of BRAF and KRAS
mutation status can be used as a strong argument
against the theoretical possibility of a mixed ‘colli-
sion’ polyp [6]. Mixed BRAF/KRAS status was not
seen, either in our study or in the 32 studies reported
previously. Beyond this basic knowledge, it should
be noted which aspects of each lesion need further
attention (overview given in Figure 6).
Classical adenoma
Higher degrees of villosity in CAD have been associ-
ated with higher rates of KRAS mutation [39]. Our
series showed a similar tendency, but the association
could not be statistically confirmed due to the very
small number of cases of pure villous adenoma.
Some villous CADs show an overlap with TSA.
These subtypes have been recently presented as (low)
serrated tubulovillous adenomas of the large intestine
[41]. Cut-offs for serration patterns, eg the proposal
of 20% serration [52] or predominant serration
(meaning> 50%) [41], are open for discussion. Addi-
tionally, secondary serration patterns in high grade
dysplasia due to general elevated proliferation should
Table 3. KRAS type of mutation
Type of mutation N5 total CAD HPP SSA SSA-D TSA
pGly12Asp 27 9 7 2 0 9
pGly12Val 23 8 4 1 0 10
pGly12Cys 9 5 2 2 0 0
pGly12Ser 2 2 0 0 0 0
pGly12Ala 2 0 0 0 0 2
pGly12Arg 1 0 0 0 0 1
pGly13Asp 6 4 0 0 0 2
pGln61Lys 6 1 3 1 1 0
Figure 4. ROC curve analysis of MLH1 and IEL accuracy. Direct
comparison of ROC curves of MLH1 hyper-methylation and IEL
counts and their diagnostic potential to detect SSA-D. The ROC
curve of MLH1 methylation revealed an AUC of 0.779. The ROC
curve of IELs was slightly better with an area of 0.861 under
the curve. Both parameters were highly significant (p< 0.001).
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be taken into account (Supplemental Figure 1). In
general, more studies dissecting the morphologically
distinct regions, as we did in SSA-D, are necessary
in this field.
Hyperplastic polyps
In contrast to statements from early investigations
conducted long before the latest WHO classification,
BRAF mutation is rare in HPP as BRAF is the main
initiating mutation event. Comparison of HPP in
micro-vesicular, mucin-depleted and goblet cell-rich
HPP revealed a slight enrichment of KRAS mutation
in the latter. Therefore, as suggested previously [1],
micro-vesicular and mucin-depleted HPP may be the
progenitors of SSA rather than goblet cell-rich HPP.
Sessile serrated adenoma
SSA showed the highest incidence of BRAF muta-
tions, which seem to be essential for this lesion. SSA
later showed a slow increase in CDKN2A methylation
preceding MLH1 methylation. This indicates that
altered senescence could be an earlier biological
event in the development of this lesion [51].
Traditional serrated adenoma
In the morphological analysis, TSAs showed an exo-
phytic growth pattern, hyper-eosinophilia and the
presence of ectopic crypt foci. At the molecular
level, either BRAF or KRAS mutations were present
in more than 80% of TSAs. Although molecularly
different the lesions showed the same morphology
Figure 5. Paired analysis of SSA-Ds with corresponding dissected areas of background SSA. (A) Methylation patterns of corresponding
areas of SSA and SSA-D within single lesions did not show differences regarding CDKN2A, but tended to show an increase in MLH1
methylation. The inflammatory response (B), however, showed significantly higher levels of IELs in dysplastic areas, whereas IEGs
remained randomly distributed. Paired Student’s t-tests, values are outlined as means with error bars of one standard deviation.
Figure 6. Histology overview. Histological overview of samples
diagnosed according to the latest WHO classification: CAD (A,
B), HPP (C, D), SSA (E, F) corresponding SSA-D areas (E, G) and
TSA (K, L). Of note, some authors suggest that SSA-Ds are sepa-
rated into conventional type SSA-D (G) or serrated type SSA-D
(H, I). Left 40x, right 200x magnification.
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[27,37]. CDKN2A methylation levels in TSA were
also elevated, showing disturbed senescence within
these lesions. However, the MLH1 methylation level
was normal in TSA. Even though the ‘dysplastic’
senescent cells in TSA more or less resemble duode-
nal mucosa, this high rate of mutations argues against
a presumably metaplastic concept [53], but favour a
truly adenomatous lesion. It has recently been shown
by Chetty et al [46] that TSAs contain adjacent areas
of CAD, HP or SSA in almost half of all polyps. As
no molecular data were collected in this study, this
morphological phenomenon should be discussed with
care. There is a well-known overlap between CAD
and TSA, which has led to different controversial
thresholds for the amount of serration. Long ago, the
term ‘substantial serration’ was sufficient [9], but this
has been replaced by thresholds of 20% [52] or the
recent predominant serration model (>50%) [41,46].
Therefore, we outlined the mean serration and its
range in TSA.
HPP-like areas adjacent to TSA were found in
approximately one-sixth of the lesions. These areas
were regarded by us as a rather hyperplastic edge
phenomenon as they also occurred in large lesions.
Unless dissection studies are performed, it remains
unknown whether these HPP areas are the soil for
TSA growth or are hyperplastic reactive changes
[46].
In contrast to the proposal of Chetty et al, the pres-
ence of an SSA as a background lesion in a true dys-
plastic lesion justifies the term SSA-D according to
the WHO [1]. At first glance, attempts to separate
TSA from an SSA-D with a serrated pattern seem
confusing (see below). However, clear molecular dif-
ferences, eg a KRAS mutation would favour TSA.
The same is true for inflammatory changes, as in our
study higher rates of IELs indicated a serrated type
dysplasia within an advanced SSA-D instead of a
TSA. The remnant SSA concept proposed by the
WHO only applies for ‘caught in the act’ lesions and
tumour overgrowth might lead to the diagnosis of a
TSA due to the vanished background SSA. This
might be one reason for the two pathways of TSAs
distinguished by BRAF or KRAS mutation [34,53].
Sessile serrated adenoma with dysplasia
To date, the diagnosis of SSA-D has been based on
having an SSA as the background lesion. The dys-
plastic areas could occur in a conventional type dys-
plasia resembling classical adenomatous regions. As
stated above, a second type of morphology has been
shown in SSA-D, involving a serrated structure [45].
Both types of dysplastic area were present in the
study and showed no distinct molecular features. Of
note, reactive inflammatory changes other than ero-
sions and acute neutrophil granulocyte infiltration
should be excluded (Supplemental Figure 1). SSA-D
often shows a high number of BRAF mutations, like
its regular SSA counter-part. Exceptionally, we found
one SSA-D with a rare exon 61 KRAS mutation but
this was combined with MLH1 hyper-methylation
and high IEL counts. Micro-dissection of the SSA
part of this polyp was not feasible and the complete
lesion was analysed as one. However, in this and all
other SSA-D there was no contradictory mutational
status in the pooled or micro-dissected situation. As
reported previously, this contradicts the concept of a
mixed polyp [6]. The loss of MLH1 seems to be
exclusively restricted to SSA-D. Additionally, the
evidence from this molecular analysis for a progres-
sion model from SSA towards SSA-D supports the
conventional as well as the serrated type of dysplasia
in SSA-D.
Introducing the immune response in colorectal
polyps to the serrated pathway to CRC
Taking a closer look at the assumed model of pro-
gression from certain HPP to SSA to SSA-D, the ini-
tiating mutator event, which is already present in
HPP, is BRAF mutation, as is proposed in the WHO
model. During tumour progression, CDKN2A hyper-
methylation increases, leading to loss of p16. This
process can be seen as proof of the concept of onco-
genically induced cell senescence [51]. In SSA-D,
the loss of MLH1 leads to the accumulation of muta-
tions and, therefore, the occurrence of true dysplastic
areas. This step is believed to be the turning point
towards sporadic MSI high tumours [48].
This hyper-mutated genotype induces immunogenic
missense proteins, which stimulate a lymphocyte-rich
immune response as seen in medullary colorectal
carcinoma.
Although right-sided MSI-high CRC subtypes
share several morphological features of SSA-D, IELs
in different serrated colorectal polyps have never
been comprehensively investigated. This includes
several inter-observer studies searching for the best
criteria for HPP, SSA and TSA [1,5–7]. Studies on
IELs in regular CADs are rare too. In Lynch syn-
drome patients, elevated numbers of IELs were found
in polyps with mismatch repair (MMR) loss, but not
in the control group with maintained MMR [54].
Three other studies focussed on immunogenic events
mainly in CADs. One showed an elevation of cyto-
toxic T-cells in high grade dysplasia [55]. McLean
et al presented a very precise profile of macrophages
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in CAD [56]. Pai et al used IELs as one of the crite-
ria to define different subtypes of CAD in patients
with and without synchronous SSA [57]. However,
the different subtypes of serrated polyps have never
previously been segregated using this feature.
The strong evidence for high IEL rates in the dys-
plastic part of SSA-D indicates that these areas are
not the same as CAD areas, but biologically distinct
as an early reaction to a hyper-mutant genotype. The
WHO classification currently has no positive crite-
rion for SSA-D. In our series, high numbers of IELs
were highly specific for SSA-D areas and exceeded
the performance of detectable MLH1 hyper-
methylation as a diagnostic marker.
Perspectives and limitations for use in daily
routine diagnostics
We chose to rely on molecular features of the polyps
for diagnosis. Therefore, this study is limited by the
use of H&E staining alone to judge the immune
response occurring in the polyps. We assume that the
infiltrates were T-lymphocytes rather than B-
lymphocytes as there was no visible increase in
plasma cells. However, an immuno-histochemical
sub-classification and increased numbers of investi-
gated SSA-D are warranted for confirmation.
It should also be noted that higher levels of IELs
could occur in different settings of immunogenic
events. High grade dysplasia can show an increase in
IELs [55] and hot spots of IELs may occur in
advanced gigantic CADs with an accumulation of
mutations. All other causes of a possibly altered
immune response, such as inflammatory bowel dis-
eases, bowel obstruction and disturbed microbial
flora should be considered during careful differential
diagnosis. However, this series was representatively
taken from general colorectal surveillance and con-
tained polyps of similar small size (mostly <2.0 cm)
in as yet untreated patients. Of note, SSA-D shows
the potential for highly accelerated progression
towards carcinoma [14]. Therefore, larger lesions are
extraordinarily rare.
As an advantage, counting IELs is a well-
established H&E technique in routine pathology.
Taken together, we have shown that higher rates of
IELs distinguish the dysplastic areas in an SSA-D
from CAD. This morphological difference can be
used as a further argument against the concept of a
‘mixed polyp’ [6] and fit very well into the serrated
carcinogenesis model with phenotypic features of
medullary carcinoma.
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SUPPLEMENTARY MATERIAL ON THE INTERNET
The following supplementary material may be found in the online version of this article:
Supplemental Table 1. Study overview
Supplemental Figure 1. Pitfalls in the diagnosis of serrated lesions. As is known in other fields of gastrointestinal pathology, eg Barrett’s
mucosa etc, severe inflammatory changes and erosions should not be overestimated as dysplasia in HPP and SSA (A). Be aware of focal sec-
ondary serrations in CAD due to higher proliferation in areas of high grade dysplasia (B).
Supplemental Figure 2. Endoscopic appearance of SSA, SSA-D and TSA: The endoscopic appearance of SSA-D and TSA could only be
assessed in a few samples (SSA, SSA-D and TSA, n5 3 for each). For a systematic endoscopic analysis, we refer to a recent study by Burgess
et al . However, an endoscopic comparison of SSA versus SSA-D and TSA could be made. SSA (A) showed the typical flat appearance with
diffuse margins. SSA-D (B) gave the impression of a ‘polyp in a polyp’. The completely flat lesion is marked by black arrow-heads and corre-
sponds to a typical SSA. A more polypoid structure with altered pit-pattern is visible on the left side of the white arrowhead, presumably
reflecting the dysplastic parts in SSA-D. TSA (C) shows a predominantly exophytic growth pattern.
124 TT Rau et al
VC 2016 The Authors The Journal of Pathology: Clinical Research published by
The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd
J Path: Clin Res April 2016; 2: 113–124
